A recent study from Howard Hughes Medical Institute, Center for Stem Cell Biology, NYU School of Medicine, 550 First Avenue, New York, USA has reported the role of Notch-regulated lncRNA LUNARI in Acute Leukemia. This study was published in the July 31 2014 Cell (The number 1 journal in basic biology) by Prof Iannis Aifantis, Thomas Trimarchi and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for Human Leukemia: Rhamnetin, an O-methylated flavonol isolated from cloves, inhibits acute leukemia via down regulation of Notch-regulated pro-oncogenic lncRNA LUNAR1. This study suggests that Rhamnetin, by decreasing the expression of Notch-1 and lncRNA LUNAR1, it may inhibit acute leukemia. Together, this study suggests that pharmacological formulations encompassing “Rhamnetin or its analogues” may be used to treat patients suffering from leukemia.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Natural product-based therapy for Human Leukemia: Rhamnetin, an O-methylated flavonol isolated from cloves, inhibits acute leukemia via down regulation of Notch-regulated pro-oncogenic lncRNA LUNAR1, 4/August/2014, 8.03 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
